Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
4 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.

Starting cabazitaxel early improves efficacy against CRPC

11 Apr 2020

Cabazitaxel is maximally effective against castration-resistant prostate cancer (CRPC) if used early, before disease progression, a recent study has shown. Dosing should be maintained carefully, however, because of the possibility of side effects.

Using a mailed questionnaire, researchers evaluated the use patterns and associated outcomes of cabazitaxel across 11 healthcare institutions, involving 55 patients (median age, 73 years). The median prostate-specific antigen (PSA) level at the start of cabazitaxel therapy was 34.14 ng/mL, with a median Gleason score of 9 at diagnosis. Thirty-four patients were positive for metastasis.

The median time to CRPC was 13 months, and patients took around four drugs each before cabazitaxel, which was given at an initial dose of 20 mg/m2 for 4 weeks.

Thirty-two patients responded to cabazitaxel and experienced decreases in PSA levels. These participants had been treated for a median of 3.5 courses, leading to a median overall survival of 13.0 months. PSA concentration at treatment onset was the only factor significantly associated with the efficacy of cabazitaxel treatment (hazard ratio, 2.32, 95 percent confidence interval, 1.18–4.57; p=0.015).

This suggests that “treatment should be administered as soon as possible before prostate cancer progresses,” and that this should be cautiously maintained even if adverse events arise.

For example, while median white blood cell and neutrophil counts dropped to very low levels during the first cabazitaxel course, triggering grade 3 and 4 leukocytopoenia, these tended to even out during the second course. Leukocytopoenia, in turn, occurred less frequently.

Editor's Recommendations
Most Read Articles
Elvira Manzano, 3 days ago
Monthly injections of the PCSK9* monoclonal antibody evolocumab effectively reduced plasma LDL-cholesterol (LDL-C), often referred to as the bad cholesterol, in teenagers with heterozygous familial hypercholesterolaemia (HeFH) already taking statins, with or without ezetimibe, the HAUSER-RCT has shown.
Jairia Dela Cruz, 3 days ago
For individuals with type 2 diabetes, losing weight is everything when it comes to improving the metabolic function, and it matters little whether this is achieved by dieting or undergoing bariatric surgery, according to a small study.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
4 days ago
In patients with type 2 diabetes (T2D), postprandial hyperglycaemia and hypertriglyceridemia worsens survival outlook, finds a new study.